Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin metabolic intervention before neoadjuvant chemoradiotherapy in resectable oesophageal adenocarcinoma
NL-OMON60474Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in esophageal adenocarcinoma (EAC), sponsored by Amsterdam University Medical Center. Primary endpoint: Tumour immune metabolic switch. Started Mar 2025; status: recruiting.
02
Drugs
metformin
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON60474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60474.